Christoph Wanner
University of Leicester
2 papers in the Anchorcite directory, published between 2015 and 2020, cited 18,064 times in total.
ORCID profileResearch topics
- Diabetes Treatment and Management · 2 papers
- Heart Failure Treatment and Management · 2 papers
- Diabetes, Cardiovascular Risks, and Lipoproteins · 1 paper
- Chronic Kidney Disease and Diabetes · 1 paper
Frequent co-authors
- Bernard Zinman · 1 paper
- John M. Lachin · 1 paper
- DAVID H. FITCHETT · 1 paper
- Erich Bluhmki · 1 paper
- Stefan Hantel · 1 paper
- Michaela Mattheus · 1 paper
- Theresa Devins · 1 paper
- Odd Erik Johansen · 1 paper
Papers
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine · 2015 · 12,596 citations
BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to…
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…
Metadata from OpenAlex (CC0).